Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Core Viewpoint - Organon's upcoming quarterly earnings report is anticipated to show a slight decline in earnings per share but a modest increase in revenue compared to the previous year [1] Financial Performance - Expected quarterly earnings of $0.85 per share, a decrease of 2.3% year-over-year [1] - Forecasted revenues of $1.56 billion, reflecting a year-over-year increase of 2.7% [1] - Analysts have revised the consensus EPS estimate upward by 1.1% over the past 30 days [1] Revenue Estimates by Segment - Revenue from Women's Health - Nexplanon/Implanon NXT is estimated at $238.19 million, indicating an 8.3% increase year-over-year [3] - Revenue from Women's Health - Follistim AQ is projected at $66.32 million, showing a 22.8% increase from the prior year [4] - Total revenue from Biosimilars is expected to reach $168.58 million, reflecting an 18.7% increase year-over-year [4] - Total revenue from Women's Health is estimated at $452.30 million, indicating an 8.2% increase from the previous year [5] - Revenue from Women's Health - U.S. - Nexplanon/Implanon NXT is projected at $164.46 million, a 12.6% increase year-over-year [5] - Geographic revenue from the U.S. is expected to be $400.64 million, reflecting an 8.3% increase from the prior year [6] - Revenue from Women's Health - U.S. - NuvaRing is expected to decline to $10.08 million, a decrease of 44% year-over-year [6] - Revenue from Women's Health - U.S. - Follistim AQ is projected at $25.52 million, indicating a 16% increase from the previous year [7] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Other is expected to be $69.71 million, a slight decrease of 0.4% year-over-year [8] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Diprospan is projected at $34.34 million, reflecting a 10.8% increase [8] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Fosamax is expected to be $35.27 million, a decrease of 11.8% year-over-year [9] Stock Performance - Over the past month, Organon's shares have declined by 10.5%, while the Zacks S&P 500 composite has increased by 2% [9] - Organon currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [9]